ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gene Expression"

  • Abstract Number: 0083 • ACR Convergence 2024

    Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice

    Mariia Korshko1, Shaghayegh Foroozan Boroojeni2 and Nigil Haroon3, 1University Health Network, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
  • Abstract Number: 0953 • ACR Convergence 2024

    Establishment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension Specific Endothelial Cells Through iPSCs and Their Functional and Molecular Analyses

    Yuki Kudo1, Masaru Kato1, Yuhei Shibata2, Ryo Hisada1, Michihito Kono1, Yuichiro Fujieda1, Olga Amengual3 and Tatsuya Atsumi1, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 2Rheumatology Department, Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan., Sapporo, Japan, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Background/Purpose: Systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) is of particularly clinical interest since its outcomes remain unfavorable despite modern PAH therapies. Previous reports showed…
  • Abstract Number: 1839 • ACR Convergence 2024

    PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways

    Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
  • Abstract Number: 0079 • ACR Convergence 2023

    CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles

    Amit Lakhanpal1, Kazuyoshi Ishigaki2, Anvita Singaraju1, Alejandro Kochen3, Miriam Fein1, Soumya Raychaudhuri4 and Laura Donlin1, 1Hospital for Special Surgery, New York, NY, 2RIKEN, Tokyo, Japan, 3Yale School of Medicine, New Haven, CT, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
  • Abstract Number: 1695 • ACR Convergence 2023

    Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis

    Philip Carlucci1, Jasmine Shwetar2, Siddarth Gurajala3, Qian Xiao3, Joseph Mears4, Katie Preisinger1, Devyn Zaminski5, Kristina Deonaraine1, Peter Izmirly1, Andrea Fava6, Judith James7, Joel Guthridge7, Brad Rovin8, Sethu Madhavan8, Wade DeJager7, David Wofsy9, Ming Wu2, Chaim Putterman10, Deepak Rao11, Betty Diamond12, Derek Fine13, Jose Monroy-Trujillo13, Kristin Haag14, H Michael Belmont5, William Apruzzese11, Anne Davidson12, Fernanda Payan-Schober15, Richard Furie16, Paul Hoover11, Celine Berthier17, Maria Dall'Era9, Kerry Cho18, Diane L. Kamen19, Kenneth Kalunian20, Jennifer Anolik21, Arnon Arazi22, Soumya Raychaudhuri11, Nir Hacohen23, Michelle Petri24, Robert Clancy25, Kelly Ruggles2, Jill Buyon25 and The Accelerating Medicines Partnership in RA/SLE26, 1New York University School of Medicine, New York, NY, 2NYU Langone, New York, NY, 3Harvard Medical School, Boston, MA, 4Michigan University, Ann Arbor, MI, 5NYU School of Medicine, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Ohio State University, Columbus, OH, 9University of California San Francisco, San Francisco, CA, 10Albert Einstein College of Medicine, Bronx, NY, 11Brigham and Women's Hospital, Boston, MA, 12Feinstein Institutes for Medical Research, Manhasset, NY, 13Johns Hopkins School of Medicine, Baltimore, MD, 14Thomas Jefferson University, Philadelphia, PA, 15Texas Tech University Health Sciences Center, El Paso, TX, 16Northwell Health, Manhasset, NY, 17University of Michigan, Ann Arbor, MI, 18UCSF Health, San Francisco, CA, 19Medical University of South Carolina, Charleston, SC, 20University of California San Diego, La Jolla, CA, 21University of Rochester Medical Center, Rochester, NY, 22Broad Institute of MIT and Harvard, Melrose, MA, 23Broad Institute of MIT and Harvard, Cambridge, MA, 24Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 25NYU Grossman School of Medicine, New York, NY, 26Multiple, Bethesda, MD

    Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
  • Abstract Number: 0112 • ACR Convergence 2023

    Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome

    Amala Ambati1, Feiyang Ma1, Katarina Kmetova1, Sherwin Navaz1, Claire Hoy1, Cyrus Sarosh1, Ajay Tambralli1, Johann E. Gudjonsson1, J. Michelle Kahlenberg1, Jacqueline Madison1, Ali Duarte-Garcia2, Jason Knight1 and Yu Zuo1, 1University of Michigan, Ann Arbor, MI, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
  • Abstract Number: 1709 • ACR Convergence 2023

    Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction

    Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
  • Abstract Number: 0114 • ACR Convergence 2023

    Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS

    Yu Shi1, Xiaofan Luo2, Quan Chen3, Jiuliang zhao4, Mengtao Li4 and xiaofeng Zeng5, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Nankai University, Tianjin, China, 3Nankai University, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
  • Abstract Number: 1738 • ACR Convergence 2023

    Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis

    Brianne Barker1, Órla Tynan2, Conor Smith3, Dumitru Anton4, Carl Orr5, Mary Canavan6, Douglas Veale7 and Ursula Fearon8, 1Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Rheumatic and Arthritic Diseases, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, 2Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 3Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, 4Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 5EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 6Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 7St.Vincent's University Hosp, Dublin, Ireland, 8Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Recent literature has identified different synovial fibroblast (FLS) populations within RA synovium with distinct inflammatory profiles. Despite current advances in classifying heterogeneity of FLS…
  • Abstract Number: 0265 • ACR Convergence 2023

    Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

    Prerak Desai1, Patrick Branigan2, Dylan Richards1, Dennis McGonagle3, Marion Vetter1, Daniel J. Cua1 and Thomas Freeman1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Minneapolis, MN, 3Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: The combination treatment of golimumab (GOL), a tumor necrosis factor-alpha (TNFα) antagonist, and guselkumab (GUS), an interleukin (IL)-23 inhibitor was shown to induce higher…
  • Abstract Number: 1762 • ACR Convergence 2023

    Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 0594 • ACR Convergence 2023

    Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease

    Panagiotis garantziotis1, Georgia-Savina Moysidou2, stavros doumas3, Dionysis nikolopoulos2, Sofia Flouda4, Noemin kapsala2, Anastasia Filia2, George Sentis2, Antonis Fanouriakis2, George Bertsias5 and Boumpas Dimitrios6, 1Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 4Unit of Attikon University Hospital, Athens, Greece, 5Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, 6National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
  • Abstract Number: 1770 • ACR Convergence 2023

    Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis

    Hee Sung Kwon1, Mi Hyeon Kim2, Jeoung Yeon Kim2, Seon Uk Kim2, Hae Rim Kang1, Seo Yoon Ban3, Gyong Sik Ha4, Chung Min Lee4, Jeong Seok Lee5 and Eun Young Lee2, 1Interdisciplinary Program in Cancer Biology, Integrated Major in Innovative Medical Science, Seoul National University, Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea, 3Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Seoul, South Korea, 4Research institute, IMBiologics Corp, Suwon, South Korea, 5Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Seoul, South Korea

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease that leads to progressive cartilage and bone destruction. TNF superfamily member OX40 ligand (OX40L; CD252) is…
  • Abstract Number: 0598 • ACR Convergence 2023

    Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

    Richard Furie1, Victoria Werth2, Eric Milliman3, Kyle Ferber3, Fergal Casey3, Roland Brown3, Denitza Raitcheva3, Jad Zoghbi3, Danielle Graham3, George Kong3, Youmna Lahoud3, Nathalie Franchimont4 and Catherine Barbey5, 1Northwell Health, Manhasset, NY, 2University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Biogen, Cambridge, MA, 4Former employee of Biogen, Cambridge, MA, 5Biogen, Baar, Switzerland

    Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
  • Abstract Number: 1791 • ACR Convergence 2023

    Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622

    James Sullivan1, Vandana Rai2, Jennifer Harvey2, Vincent Del Signore2, Unnikrishnan Chandrasekharan2 and M. Elaine Husni3, 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH

    Background/Purpose: Despite the widespread use of anti-TNFα therapy in psoriatic arthritis (PsA), a significant proportion of patients fail to achieve a complete treatment response. There…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology